Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of New Brunswick

$20,000.00

L2M NSERC - A multiplex electrochemical sensing platform for early detection of breast cancer biomarkers

FY 2023-24

Summary
Accounting for a quarter of all cancers in women, breast cancer (BC) is the most common cancer globally. Currently, BC is detected using mammography and routine breast examination. Unfortunately, overdiagnosis/false positives associated with mammography can increase patient anxiety and, at times, unnecessary biopsy. Additionally, mammography presents several confounding variables such as physician interpretation, poor positioning, and tumor sub-types that can result in as many as 30% of breast cancers going undetected. Breast cancer is a diverse disease with various subtypes, genetic mutations, and DNA damage and is categorized into five immunohistochemical subtypes. Additionally, other forms of disease classification consider the stage-dependent biomarkers of BC that are diagnostic, prognostic, predictive, and therapeutic biomarkers. Therefore, together with the confirmation of BC from quantification of HER2 marker, identifying the above-listed subcategories of BC would also represent an upgrade in breast cancer diagnostics and thus subsequent care.In the proposed invention we develop a new diagnostic tool to address two important limitations of current analytical assay. Firstly, the new prototype has a limit of detection for HER2 marker significantly lower than current assays, making it suitable for early BC screening (stage I and II). Secondly, we have integrated several sensors into the one multiplex platform to simultaneously detect a range of BC biomarkers.The proposed biomarker multi-analyte blood tester is lightweight, portable, battery-operated, and wirelessly controlled, so it can be easily relocated or even used outside of medical laboratories. This biomarker assay enables medical staff to make treatment decisions without in-person appointments, thus accelerating the start of treatment, improving prognosis for patients, and providing important therapeutic guidelines for health practitioners that can access and monitor the disease status remotely.
Program
Idea to Innovation
Location
New Brunswick, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
590719-2024
Name nom
Ignaszak, Anna AI
Department département
Chemistry
Organization id
75
Institution établissement
University of New Brunswick
Province en
New Brunswick
Province fr
Nouveau-Brunswick
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
9100
Research subject group en
Recherche biomédicale
Research subject group fr
Medical sciences
Research subject en
Biomedical
Research subject fr
Sciences médicales
Application title
L2M NSERC - A multiplex electrochemical sensing platform for early detection of breast cancer biomarkers
Keyword
breast cancer; cancer biomarkers; cancer diagnostics; early screening; electrochemical biosensors; electrochemistry; electrode array; electrode prototyping; multiplex sensor; point-of-care
Application summary
Accounting for a quarter of all cancers in women, breast cancer (BC) is the most common cancer globally. Currently, BC is detected using mammography and routine breast examination. Unfortunately, overdiagnosis/false positives associated with mammography can increase patient anxiety and, at times, unnecessary biopsy. Additionally, mammography presents several confounding variables such as physician interpretation, poor positioning, and tumor sub-types that can result in as many as 30% of breast cancers going undetected. Breast cancer is a diverse disease with various subtypes, genetic mutations, and DNA damage and is categorized into five immunohistochemical subtypes. Additionally, other forms of disease classification consider the stage-dependent biomarkers of BC that are diagnostic, prognostic, predictive, and therapeutic biomarkers. Therefore, together with the confirmation of BC from quantification of HER2 marker, identifying the above-listed subcategories of BC would also represent an upgrade in breast cancer diagnostics and thus subsequent care.In the proposed invention we develop a new diagnostic tool to address two important limitations of current analytical assay. Firstly, the new prototype has a limit of detection for HER2 marker significantly lower than current assays, making it suitable for early BC screening (stage I and II). Secondly, we have integrated several sensors into the one multiplex platform to simultaneously detect a range of BC biomarkers.The proposed biomarker multi-analyte blood tester is lightweight, portable, battery-operated, and wirelessly controlled, so it can be easily relocated or even used outside of medical laboratories. This biomarker assay enables medical staff to make treatment decisions without in-person appointments, thus accelerating the start of treatment, improving prognosis for patients, and providing important therapeutic guidelines for health practitioners that can access and monitor the disease status remotely.
University of New Brunswick - $20,000 Grant (2023-24) | Canada Spends